Toxicology and Diseases Group (TDG), Pharmaceutical Sciences Research Center (PSRC), The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.
Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Expert Opin Pharmacother. 2019 Dec;20(17):2073-2080. doi: 10.1080/14656566.2019.1668927. Epub 2019 Sep 26.
: Chronic idiopathic constipation (CIC) is a kind of constipation in which the patient experiences constipation more than 3 months without any identifiable cause. Prucalopride is one such treatment considered for relieving symptoms of CIC regarding due to its selectivity for the 5HT4 receptor.: This article is based on a PubMed and clinicaltrials.gov search for studies undertaken over the past 19 years (2000-2019) using the following keywords either alone or in combination: Prucalopride, chronic idiopathic constipation, chronic constipation, 5HT4 receptor, Resolor and Motegrity.: Prucalopride should be considered as one of the safe options for the treatment of CIC especially when previous treatments have failed. It can be helpful in the treatment of constipation caused by irritable bowel syndrome or spinal cord injury, opioid-induced constipation, post-operative ileus, and intestinal/colonic pseudo-obstruction. The major drawback of prucalopride is its high cost, which makes it less accessible to all patients.
慢性特发性便秘(CIC)是一种患者经历便秘超过 3 个月而没有任何可识别原因的便秘。普芦卡必利是一种被认为可以缓解 CIC 症状的治疗方法,因为它对 5HT4 受体具有选择性。本文基于过去 19 年(2000-2019 年)在 PubMed 和 clinicaltrials.gov 上进行的研究,使用以下关键词单独或组合使用:普芦卡必利、慢性特发性便秘、慢性便秘、5HT4 受体、Resolor 和 Motegrity。普芦卡必利应被视为治疗 CIC 的安全选择之一,特别是在以前的治疗失败的情况下。它可以帮助治疗由肠易激综合征或脊髓损伤、阿片类药物引起的便秘、术后肠梗阻和肠/结肠假性梗阻引起的便秘。普芦卡必利的主要缺点是其成本高,这使得并非所有患者都能获得该药。